CN115461340A - 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物 - Google Patents

具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物 Download PDF

Info

Publication number
CN115461340A
CN115461340A CN202180023434.1A CN202180023434A CN115461340A CN 115461340 A CN115461340 A CN 115461340A CN 202180023434 A CN202180023434 A CN 202180023434A CN 115461340 A CN115461340 A CN 115461340A
Authority
CN
China
Prior art keywords
disease
compound
cancer
tautomer
deficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180023434.1A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·卢克霍斯特
M·I·肯普
P·W·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mission Therapeutics Ltd
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2005250.2A external-priority patent/GB202005250D0/en
Priority claimed from GBGB2016607.0A external-priority patent/GB202016607D0/en
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of CN115461340A publication Critical patent/CN115461340A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180023434.1A 2020-04-08 2021-04-07 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物 Pending CN115461340A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2005250.2A GB202005250D0 (en) 2020-04-08 2020-04-08 Novel compounds
GB2005250.2 2020-04-08
GBGB2016607.0A GB202016607D0 (en) 2020-10-20 2020-10-20 Novel Compounds
GB2016607.0 2020-10-20
PCT/EP2021/059032 WO2021204856A1 (en) 2020-04-08 2021-04-07 N-cyanopyrrolidines with activity as usp30 inhibitors

Publications (1)

Publication Number Publication Date
CN115461340A true CN115461340A (zh) 2022-12-09

Family

ID=75441909

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180023434.1A Pending CN115461340A (zh) 2020-04-08 2021-04-07 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物

Country Status (13)

Country Link
US (1) US20230119013A1 (https=)
EP (1) EP4132925A1 (https=)
JP (1) JP2023520727A (https=)
KR (1) KR20230006487A (https=)
CN (1) CN115461340A (https=)
AU (1) AU2021253617A1 (https=)
BR (1) BR112022020058A2 (https=)
CA (1) CA3171349A1 (https=)
CO (1) CO2022014134A2 (https=)
IL (1) IL296998A (https=)
MX (1) MX2022012578A (https=)
WO (1) WO2021204856A1 (https=)
ZA (1) ZA202212137B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117887844A (zh) * 2023-12-28 2024-04-16 中山大学附属第一医院 Usp20在肝癌放疗增敏中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016240033A1 (en) * 2015-03-30 2017-11-09 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
GB201905371D0 (en) * 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
WO2020036940A1 (en) * 2018-08-14 2020-02-20 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
EP1272467A4 (en) 2000-04-06 2003-05-07 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
SG174050A1 (en) 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
US20090264431A1 (en) 2007-08-20 2009-10-22 Palovich Michael R Novel cathepsin c inhibitors and their use
WO2009129371A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2009129365A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
RS58361B1 (sr) 2013-07-31 2019-03-29 Merck Patent Gmbh Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba
US9963444B2 (en) 2014-05-19 2018-05-08 Northeastern University N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
US20170095457A1 (en) 2014-05-27 2017-04-06 David Lonergan Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
CN108884068B (zh) 2016-03-24 2021-02-26 特殊治疗有限公司 作为dub抑制剂的1-氰基-吡咯烷衍生物
US11014912B2 (en) 2016-09-27 2021-05-25 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
AU2018346597B2 (en) * 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
JP7530889B2 (ja) 2018-10-05 2024-08-08 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016240033A1 (en) * 2015-03-30 2017-11-09 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
WO2020036940A1 (en) * 2018-08-14 2020-02-20 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
GB201905371D0 (en) * 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117887844A (zh) * 2023-12-28 2024-04-16 中山大学附属第一医院 Usp20在肝癌放疗增敏中的应用

Also Published As

Publication number Publication date
MX2022012578A (es) 2022-11-07
IL296998A (en) 2022-12-01
KR20230006487A (ko) 2023-01-10
BR112022020058A2 (pt) 2022-11-22
AU2021253617A1 (en) 2022-12-01
JP2023520727A (ja) 2023-05-18
ZA202212137B (en) 2024-07-31
EP4132925A1 (en) 2023-02-15
CA3171349A1 (en) 2021-10-14
WO2021204856A1 (en) 2021-10-14
US20230119013A1 (en) 2023-04-20
CO2022014134A2 (es) 2022-10-31

Similar Documents

Publication Publication Date Title
CN114341133B (zh) 具有usp30抑制剂活性的取代的氰基吡咯烷类
CN115461340A (zh) 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物
WO2020212350A1 (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors
JP7796047B2 (ja) Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン
CN115667252A (zh) 用于治疗线粒体功能障碍的作为usp30抑制剂的n-(1-氰基-吡咯烷-3-基)-5-(3-(三氟甲基)苯基)噁唑-2-甲酰胺衍生物和对应噁二唑衍生物
EP4161929A1 (en) 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
WO2022084479A1 (en) N-cyanopyrrolidines with activity as usp30 inhibitors
RU2822680C1 (ru) Замещенные цианопирролидины, обладающие активностью ингибиторов USP30
RU2848457C1 (ru) N-Цианопирролидины с активностью ингибиторов USP30
HK40077361A (en) N-cyanopyrrolidines with activity as usp30 inhibitors
HK40068349A (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors
HK40068349B (zh) 具有usp30抑制剂活性的取代的氰基吡咯烷类
HK40081471A (en) N-cyanopyrrolidines with activity as usp30 inhibitors
HK40081706A (en) N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077361

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221209